Header

UZH-Logo

Maintenance Infos

Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment


Opitz, Isabelle; Lardinois, Didier; Arni, Stephan; Hillinger, Sven; Vogt, Peter; Odermatt, Bernhard; Rousson, Valentin; Weder, Walter (2007). Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. European Journal of Cardio-Thoracic Surgery, 31(5):772-778.

Abstract

Objective: Local recurrence remains a major problem in the treatment of malignant pleural mesothelioma. The aim of the underlying study was to establish a standardised local recurrence model in rats which enables to study different intrapleural therapies. Materials and methods: Fifty microlitre containing 1×106 cells of a syngeneic rat malignant mesothelioma cell line (II-45), established from mesothelioma in Fischer 344 rats exposed to asbestos, were inoculated subpleurally via a left-sided thoracotomy. Tumour size was assessed 6 days later and the tumour nodule completely resected. Evaluation of recurrence at the resection site was performed after 10 days (n=6) and 6 days (n=6). The recurrent nodule was histopathologically confirmed. In a second experiment, this new recurrence model was evaluated for the effect of intrapleural therapy with different agents: 4ml of cisplatin-solution (100mg2/kg BW), cisplatin combined with the fibrin-based sealant Vivostat®, 4ml taurolidine 2%, repeated injection of 1μg of the chemokine CCL-19 at the tumour site and 4ml povidone-iodine in a dilution 1:10. In a control group, the chest cavity was filled with 4ml 0.9% NaCl. The primary endpoint was the extent of tumour recurrence. Results: Six days after inoculation, all animals presented a standardised tumour nodule at the injection site of a mean diameter of 5.1 (±0.8)mm. Evaluation of the recurrence after 10 days showed a relapse directly at the resection site, but additional tumour nodules on the ipsi- and contralateral chest wall were found and histologically confirmed. The animals that were sacrificed 6 days after resection of the tumour nodule showed a recurrence only at the resection site with no macroscopic or microscopic evidence of other tumour. Resection of the tumour nodule combined with intrapleural application of the different agents lead to clear reduction of recurrence. The strongest effect was observed after intrapleural application of cisplatin-Vivostat® with significant decrease of the longest, widest and thickest diameter of the recurrence. Conclusions: With this new recurrence model for investigation of malignant pleural mesothelioma in rats, we were able to investigate new intrapleural therapies after pneumonectomy. The intrapleural application of cisplatin-Vivostat® significantly reduced the extent of local recurrence

Abstract

Objective: Local recurrence remains a major problem in the treatment of malignant pleural mesothelioma. The aim of the underlying study was to establish a standardised local recurrence model in rats which enables to study different intrapleural therapies. Materials and methods: Fifty microlitre containing 1×106 cells of a syngeneic rat malignant mesothelioma cell line (II-45), established from mesothelioma in Fischer 344 rats exposed to asbestos, were inoculated subpleurally via a left-sided thoracotomy. Tumour size was assessed 6 days later and the tumour nodule completely resected. Evaluation of recurrence at the resection site was performed after 10 days (n=6) and 6 days (n=6). The recurrent nodule was histopathologically confirmed. In a second experiment, this new recurrence model was evaluated for the effect of intrapleural therapy with different agents: 4ml of cisplatin-solution (100mg2/kg BW), cisplatin combined with the fibrin-based sealant Vivostat®, 4ml taurolidine 2%, repeated injection of 1μg of the chemokine CCL-19 at the tumour site and 4ml povidone-iodine in a dilution 1:10. In a control group, the chest cavity was filled with 4ml 0.9% NaCl. The primary endpoint was the extent of tumour recurrence. Results: Six days after inoculation, all animals presented a standardised tumour nodule at the injection site of a mean diameter of 5.1 (±0.8)mm. Evaluation of the recurrence after 10 days showed a relapse directly at the resection site, but additional tumour nodules on the ipsi- and contralateral chest wall were found and histologically confirmed. The animals that were sacrificed 6 days after resection of the tumour nodule showed a recurrence only at the resection site with no macroscopic or microscopic evidence of other tumour. Resection of the tumour nodule combined with intrapleural application of the different agents lead to clear reduction of recurrence. The strongest effect was observed after intrapleural application of cisplatin-Vivostat® with significant decrease of the longest, widest and thickest diameter of the recurrence. Conclusions: With this new recurrence model for investigation of malignant pleural mesothelioma in rats, we were able to investigate new intrapleural therapies after pneumonectomy. The intrapleural application of cisplatin-Vivostat® significantly reduced the extent of local recurrence

Statistics

Citations

Dimensions.ai Metrics
6 citations in Web of Science®
15 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

16 downloads since deposited on 15 Nov 2018
16 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 May 2007
Deposited On:15 Nov 2018 14:48
Last Modified:17 Nov 2018 20:55
Publisher:Oxford University Press
ISSN:1010-7940
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1016/j.ejcts.2007.01.047
Related URLs:https://www.swissbib.ch/Search/Results?lookfor=nationallicenceoxford101016jejcts200701047 (Library Catalogue)
PubMed ID:17350855

Download

Download PDF  'Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 1MB
View at publisher